PDF(Pubmed)
Abstract：
Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral immune persistence has been proposed to be affected by patients\' characteristics. Moreover, available conflicting assay results are needed to be settled through comparative research with defined clinical specimens. Methods This prospective study investigated SARS-CoV-2-specific antibodies among 43 adults and 34 children at a mean of 12 weeks after the onset of COVID-19 symptoms using six serological assays and compared their performance. We used two Euroimmun (Euroimmun, Luebeck, Germany), two automated Roche Elecsys (Basel, Switzerland), and two rapid immuno-chromatographic Ecotest (Matrix Diagnostics, Assure Tech. (Hangzhou) Co., L, China) assays to investigate SARS-CoV-2 antibodies. Results The findings showed that the Roche Elecsys anti-S total test yielded the best positivity/sensitivity (children 94.1% and adults 93.0%; p = 0.877) while five immunoglobulin IgG targeting assays had similar positivity/sensitivity between children (88.2% to 94.1%) and adults (88.4% to 93.0%) (p > 0.05). Although IgM positivity was relatively low (p < 0.001), it was found in the majority of our pediatric and adult patients (67.6% and 86.0%, respectively; p = 0.098). SARS-CoV-2 S IgG titers were found to be higher among males in pediatric and adult groups compared to females (p = 0.027 and p = 0.041, respectively). Furthermore, we observed significantly higher antibody titers among pneumonia patients (p = 0.001). Conclusion Overall, we concluded SARS-CoV-2 antibody persistence over an average of 12 weeks after the onset of COVID-19 symptoms. While automated Roche Elecsys total antibody assays yielded the best sensitivity (> 90%) and five assays targeting IgG had acceptable performance. Patients with pneumonia and males have higher antibody titers. The effect of antibody persistence on re-infections should be monitored in longitudinal studies.
摘要：
介绍严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性体液免疫持久性已被认为受患者特征的影响。此外，现有的相互矛盾的检测结果需要通过与确定的临床标本进行比较研究来解决.方法这项前瞻性研究使用6种血清学检测方法，在COVID-19症状发作后平均12周，调查了43名成人和34名儿童的SARS-CoV-2特异性抗体，并比较了它们的表现。我们使用了两个Euroimmun（Euroimmun，吕贝克,德国),两个自动罗氏电子(巴塞尔，瑞士),和两个快速免疫层析Ecotest(基质诊断学，保证技术。(杭州)有限公司L,中国）检测SARS-CoV-2抗体。结果研究结果表明，RocheElecsys抗S总检测具有最佳的阳性/敏感性（儿童94.1％和成人93.0％；p=0.877），而5种免疫球蛋白IgG靶向检测在儿童（88.2％至94.1％）和成人（88.4％至93.0％）之间具有相似的阳性/敏感性（p>0.05）。尽管IgM阳性相对较低(p<0.001)，在我们的大多数儿科和成人患者中发现（67.6％和86.0％，分别为；p=0.098)。与女性相比，儿科和成人组的男性SARS-CoV-2SIgG滴度更高（分别为p=0.027和p=0.041）。此外，我们观察到肺炎患者的抗体滴度显著较高(p=0.001).结论总体来说,我们得出结论:在COVID-19症状出现后平均12周内,SARS-CoV-2抗体持续存在.虽然自动化的RocheElecsys总抗体测定产生了最好的灵敏度(>90%),并且靶向IgG的五个测定具有可接受的性能。肺炎患者和男性患者的抗体滴度较高。应在纵向研究中监测抗体持久性对再感染的影响。
